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Balancing the local and the universal in
maintaining ethical access to a genomics
biobank
Catherine Heeney1* and Shona M. Kerr2
Abstract
Background: Issues of balancing data accessibility with ethical considerations and governance of a genomics
research biobank, Generation Scotland, are explored within the evolving policy landscape of the past ten years.
During this time data sharing and open data access have become increasingly important topics in biomedical
research. Decisions around data access are influenced by local arrangements for governance and practices such as
linkage to health records, and the global through policies for biobanking and the sharing of data with large-scale
biomedical research data resources and consortia.
Methods: We use a literature review of policy relevant documents which apply to the conduct of biobanks in two
areas: support for open access and the protection of data subjects and researchers managing a bioresource. We
present examples of decision making within a biobank based upon observations of the Generation Scotland Access
Committee. We reflect upon how the drive towards open access raises ethical dilemmas for established
biorepositories containing data and samples from human subjects.
Results: Despite much discussion in science policy literature about standardisation, the contextual aspects of
biobanking are often overlooked. Using our engagement with GS we demonstrate the importance of local
arrangements in the creation of a responsive ethical approach to biorepository governance. We argue that
governance decisions regarding access to the biobank are intertwined with considerations about maintenance and
viability at the local level. We show that in addition to the focus upon ever more universal and standardised
practices, the local expertise gained in the management of such repositories must be supported.
Conclusions: A commitment to open access in genomics research has found almost universal backing in science
and health policy circles, but repositories of data and samples from human subjects may have to operate under
managed access, to protect privacy, align with participant consent and ensure that the resource can be managed
in a sustainable way. Data access committees need to be reflexive and flexible, to cope with changing technology
and opportunities and threats from the wider data sharing environment. To understand these interactions also
involves nurturing what is particular about the biobank in its local context.
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Background
In policy and governance discussions around the shar-
ing of genetic and genomic data, the rights of research
subjects are often balanced against the scientific bene-
fits of allowing open access to biomedical data [1, 2].
Here, we follow an established tradition of including
empirical worked examples, in order to engage with
ethical issues raised by providing access to data stored
within an existing biobank [3–5]. The aim is to go be-
yond a simple opposition between being open and pro-
tection of the autonomy and privacy of data subjects to
make a case for the inclusion of social and technical
considerations in assessing what is ethical. We seek to
address a gap in discussion in scientific, law and policy
arenas about standardisation [6, 7] by focusing on the
contextual aspects of biobanking, which include the
will and ability to sustain the resource [8]. We will con-
sider Generation Scotland (GS) [9] as one context in
which the global policy agenda of open access meets
local issues. This raises not only questions around eth-
ics and governance, which have been a focus of much
of the discussion around access, but also questions of
sustainability. GS is a genomics research biobank initi-
ated with a Scottish Higher Education Funding Council
grant between 2001 and 2004 and supported by the
Chief Scientist Office of the Scottish Government from
2005 to 2014 (www.generationscotland.org). Participant
recruitment and collection of data from the 24,000 plus
participants began in 2006 and a GS infrastructure con-
tinues to exist and manage access to a repository more
than a decade later. At the time of its creation Gener-
ation Scotland was described as: a “large, family-based
intensively-phenotyped cohort recruited from the gen-
eral population across Scotland, as a resource for study-
ing the genetics of health areas of current and
projected public health importance” [10].
The period of the early 2000s saw genetic biobanks
and repositories of various sorts created with the aim of
ensuring a greater openness to data sharing. Generally,
biobanks or repositories hold both genetic data and
phenotypic data sourced from research clinics and often
also eHealth records. UK Biobank and Generation
Scotland were intended to be resources with minimal re-
strictions to reuse [8]. Data and sample repositories such
as GS were a manifestation of a growing commitment
coming from science policy actors, including funders, to
promote data sharing and access to a wide range of
users. In what follows, we consider the specific charac-
teristics of the GS repository in shaping its data access
practices in light of the UK data sharing policy environ-
ment. We will use our interaction with GS to explore in
particular the issues of sustainability and evolution of
the biobank's content in relation to ethical decision mak-
ing around access.
Methods
We engage with GS as a specific example of a biobank
and our “encounters with experience” [4] gained
within the Generation Scotland Access Committee
(GSAC). Empirical studies of the perspectives of those
running biobanks point to the need to consider the
contextual aspects of biobanking [11–13]. We hope to
further elucidate these contextual aspects by focusing
on the practices of the GSAC. The authors have both
had experience of working within the GSAC. Using
GS as a case enables us to consider how a particular
repository attempts to balance locally established gov-
ernance and institutional and research relationships
with the imperative to share data as openly as pos-
sible. Through GS we explore the entwined practical
and ethical challenges around data sharing for existing
repositories [14]. By situating the ethics of access via
examples arising in an active biobank, the aim is to
ensure that our discussion goes beyond considerations
of the “what if” type, which for example balance future
health benefits against potential privacy risk questions
for an imagined future [15].
We reflect upon the processes within GS through
which requests for data access are handled. This will
include considering how the Access Committee must
deal creatively and responsively with issues not fore-
seen when the repository was first set up and as a con-
sequence, which may challenge existing governance
arrangements [16]. Therefore, we present examples of
the decision-making process of the GSAC in order to
consider how changes in the global data sharing and
governance environment, as well as internal changes
to the resource, raise ethical questions. It is in the
context of the GSAC that the wider policy field, is ne-
gotiated in relation to the characteristics of GS. Devel-
opments within the biobank and the data sharing
environment more generally can raise ethical di-
lemmas even if the consent obtained was compara-
tively broad. ‘While in an unproblematised situation,
material objects are seamlessly woven into every day
practice - family pedigrees are produced, blood sam-
ples are taken, medical records are filed away etc. In
some cases the movement of these material objects
into different physical locations, or even the particu-
larity of their arrangement or configuration, can serve
to problematize those practices’ [17]. We argue that
data sharing raises issues relating to the role of the re-
pository in future governance and ethical oversight
and ask how expectations and preferences of partici-
pants will be interpreted in future scenarios, for ex-
ample within consortia [18]. Whilst issues of
sustainability could be viewed as separate from ethical
and governance considerations, we aim to show that
they are inseparable in relation to access [19].
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Results
Generation Scotland (GS)
The GS Scottish Family Health Study was designed to
provide a research resource, adequately powered to de-
tect moderate sized genetic effects upon common and
chronic disease and traits. A family-based recruitment
strategy was employed to collect over 24,000 participants
between 2006 and 2011. Study participants were first
approached through their General Practitioner (GP)
using the Community Health Index (CHI) number (the
CHI number exists only in Scotland and is unique to
each individual in the > 96% of the Scottish population
registered with a GP) [20]. Those who indicated that
they and one or more of their relatives would participate
were sent an information leaflet, a consent form and a
preclinical questionnaire. Subsequently, comprehensive
information was collected covering demographics, bio-
metric measurements and the health of individuals and
their families, including psychological health. This was
done via a paper questionnaire which gathered ~400
data items, and during a research clinic appointment a
further ~150 items of data were collected. The member-
ship of the GSAC includes representation from NHS
Research and Development Offices, University Technol-
ogy Transfer Offices, clinical academics, scholars work-
ing on ethics and governance, and laboratory and IT
experts. The membership is renewed over time but indi-
viduals connected with the research design, recruitment
and maintenance have ongoing input. A dedicated man-
agement group responsible for implementing the access
arrangements was funded by the Chief Scientist Office
(CSO) of the Scottish Government, for an initial period of
3 years, following the completion of recruitment (the man-
agement structure of GS is illustrated in Fig. 1). Currently,
members of the GS Executive Committee, Expert Working
Groups and Access Committee give their time freely as
part of their academic or support staff duties.
The Management, Access and Publication Policy of
GS specifies that the Access Committee (GSAC) will:
manage requests for collaboration and use of Project
Data, Derived Data and NHS Data and/or Samples;
Approve or deny requests for new collaborations;
Consider and approve: Collaboration Proposal Forms
and Data and Material Transfer Agreements and Report
to the Executive on the progress of proposed collabora-
tions. It must also consider the terms of consent and
protection of confidentiality of data subjects [21]. GSAC
meetings are held approximately quarterly depending on
the volume and complexity of the proposals. The GSAC
considers a range of criteria when reviewing data access
requests, as is standard practice for Data Access
Committees operating a managed (controlled) access
process [22, 23]. Pre-screening by the GS Management
Group ensures that full reviews take place only after
funding has been obtained by the applicants and if
requested resources match GS holdings. Requests which
are considered routine are dealt with via email without
detailed discussion by the GSAC. Routine requests seek
to access data only, do not require the participants to be
re-contacted and are viewed as raising no significant
governance issues. Examples include the re-analysis of
existing anonymised genomic datasets to test and
Fig. 1 Generation Scotland (GS) Management Structure
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improve software algorithms, or to access anonymised
individual patient data according to a particular geno-
type of interest and to generate preliminary data for a
grant application. Furthermore, GSAC is notified but is
not directly involved in decisions to approve release of
GS data and/or samples for management rather than re-
search purposes to the GS management team or to aca-
demic researchers from institutions that are part of the
GS Collaboration Agreement. Approximately 20 projects
out of a total of over 250 research requests have re-
quired this type of release, which are not subject to Data
and Material Transfer Agreement signature or an access
charge. The primary purpose of these management ac-
cess requests is to test or check the quality of an aspect
of the resource. In contrast, payment must be made for
all research requests, as it was decided by the GS Execu-
tive Committee that no distinction would be made be-
tween researchers who had been involved in the GS
Collaboration Agreement and those who had not.
Policy, access and repositories in the UK
Influential genomics and medical research funder the
Wellcome Trust has long advocated data sharing and
open access [8]. In 2003 the Wellcome Trust published
an influential report, following a closed meeting in Fort
Lauderdale, Florida, intended to identify and resolve is-
sues that may form barriers to data sharing and reuse of
existing biomedical data [24]. Here a model of access
was promoted in which any studies with biomedical re-
search value could become “community resources” [24],
in opposition to what were presented as restrictive and
proprietorial governance models. This meeting itself
followed on from a meeting in Bermuda held in
February 1996, which involved leaders of the Human
Genome Project and sought to avoid some scientists
gaining an advantage by refusing to share human
sequence information in a timely manner [25]. More
recently a meeting was held in Toronto in part to deal
with technological advances in data production. This
produced the Toronto Statement of 2009, which sought
to reiterate the importance of reaffirming the ‘lessons
from Human Genome Project (HGP)’ regarding the
‘scientific value’ of rapid release of data [26]. In these
statements, collective benefits of data sharing are often
in counter-balance to more individual goods such as
privacy and professional protectionism [27]. This gener-
ates tensions between notions of public and societal
benefit from open access to large and complex biomed-
ical datasets and the need to manage access with respect
to the details of participant consent and privacy expecta-
tions [28, 29]. The Toronto Statement acknowledges that
under some circumstances, such as where detailed gen-
omic or clinical data pose a risk of deidentification of in-
dividual research subjects, ‘access may be restricted’ [26].
Some of the policy documents discussed in this section,
as we will point out, do acknowledge privacy and confi-
dentiality issues raised by data-sharing and access. More-
over, the linked issues of privacy and confidentiality have
been raised as a concern across literature produced by
stakeholders in biomedical data sharing [30]. Further
disadvantages put forward include ‘moral distance’ be-
tween new contexts for data use and sharing, and com-
promising the ability of original researchers to fulfill
commitments to research subjects. Questions about ad-
equate acknowledgement of those involved in maintain-
ing the study were also raised [8, 30]. The governance
response for extending access has often turned upon al-
tering models of consent [31, 32]. Existing resources
such as the Avon Longitudinal Study of Parents and
Children and the 1958 British Birth Cohort were encour-
aged to revisit their participant consent [33]. Newer large
scale repositories such as Generation Scotland and UK
Biobank, created to support research access by secondary
users [31], attempted to begin with broad informed con-
sent to facilitate more flexible data access arrangements.
The policy environment for data sharing continues to
abound with examples of encouragement to share. For
example, data deposition to repositories such as the
European Genome-phenome Archive (EGA) [34], a ser-
vice for permanent archiving and sharing of all types of
personally identifiable genetic and phenotypic data
resulting from biomedical research projects, is included
as a condition of publication for many key scientific
journals. However, access to resources remains frustrat-
ingly difficult for some, prompting suggestions that ac-
cess arrangements for biobanks tread a fine line between
facilitating and hindering sharing [35]. More recently the
Wellcome Trust, with the Expert Advisory Group on
Data Access (EAGDA), has produced a report address-
ing incentives and disincentives to sharing for funders,
institutions and researchers [36]. Again it is acknowl-
edged in this document that restrictions can be man-
dated ethically due to confidentiality concerns for study
participant data. However, the EAGDA report empha-
sises the importance of recognising the benefits of data
sharing, including avoiding duplication of effort and
allowing innovative and inventive uses of data already
collected [36]. A Concordat produced by Research
Councils UK (RCUK) [37], which is an umbrella
organization for the main public sector research funding
bodies in the UK, echoed these benefits and added the
potential for safeguarding against misconduct. The
RCUK Concordat does not deal exclusively with data
arising from human subjects, and is thus largely silent
on the matter of informed consent and the management
of ongoing relationships with research participants.
However, Principle 5 deals with the need for some ele-
ments of managed access. Justified restrictions to data
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access include the protection of commercial interests
and again the privacy and confidentiality of research
subjects. These documents aim for generic guidance in
which strategies for dealing with these issues appear as
high level principles. Whilst there is acknowledgement
of justified ethical restrictions to sharing, the onus is
placed on those controlling the resource to make the
case for denying access [37]. A joint review of data se-
curity, consent and opt-outs in the UK National Health
Service (NHS) and Care Quality Commission in 2016
saw Dame Fiona Caldicott, the National Data Guardian,
re-emphasise the responsibility of organisations using
NHS data to ensure both anonymity and consent [38].
Yet there is an increasingly warm view of sharing health
related data in the 2012 Caldicott report [39], where a
seventh principle added to the list of six produced in
1997 states that sharing patient data could be viewed as
equally important as the protection of patient confiden-
tiality. Indeed, access to NHS data has been promoted to
meet both healthcare and commercial interests [39].
The EAGDA suggests that consent ‘is not a panacea
and even where consent specifically allows for further
data use, robust governance is essential for the ethical
conduct of research’ suggesting a forbearing attitude to
managed access approaches [36]. The report devotes
considerable space to ensuring that governance and
other institutional arrangements promote data sharing
where possible. This report does then engage with issues
which may arise in particular contexts but opts to list a
generic set of challenges, largely focused on concerns
around protecting the privacy of individuals.
The uniqueness of the genome of an individual
coupled with even minimal phenotypic trait information
are widely accepted to pose risks to data confidentiality
and by extension the privacy of individual data subjects
[29, 40, 41]. Controversy around the publication of a key
paper in 2008 [42], which highlighted the possibility of
re-identifying an individual within an anonymized data-
set [43] led to reactive policy changes around data access
by key players, such as the Wellcome Trust and the
National Institute for Health in the U:S [1, 8]. Confiden-
tiality and security arrangements and use restrictions are
intended to mitigate against such incidents, which are
thought may have the indirect effect of undermining
trust in a particular repository, or in biomedical research
as a whole [29]. The EAGDA has acknowledged the dif-
ficulties of maintaining promises of anonymity, suggest-
ing that misuse including attempts at identification of
individual data subjects will potentially incur both legal
and funding sanctions [36]. Meanwhile those who have
sought to promote open and rapid data sharing have
shown a tendency to frame privacy concerns as a barrier
to research. Privacy and related issues such as confiden-
tiality and anonymity have themselves become a target
for those who are convinced of the benefits of open ac-
cess, with the suggestion that actual harms arising, even
where some breach is possible, are exaggerated [44].
The UK policy environment reflects an international ef-
fort to take practical steps to ensure existing data is shared
by improving the discoverability of biobanks, such as the
UK MRC Cohort Directory (https://www.mrc.ac.uk/re-
search/facilities-and-resources-for-researchers/cohort-direc-
tory/) and the UK CRC Tissue Directory (https://
www.biobankinguk.org/). The latter is part of an umbrella
organization for biobanking in Europe, BBMRI-ERIC
(Biobanking and Biomolecular Resources Research In-
frastructure), funded by the European Commission
[45]. GS is listed in these directories and also tries to
make its resources findable through the established aca-
demic routes of a study website and research publica-
tions as well as exploiting social media channels.
Recently, an international initiative for scholarly data
publishing proposed that all scientific data should be
“FAIR”- Findable, Accessible, Interoperable, and Re-
usable [46]. The Global Alliance for Genomics and
Health (GA4GH) has developed a Framework for re-
sponsible sharing of genomic and health-related data
[47]. Here the push is towards creating the conditions
of more open sharing via harmonisation: “The Global
Alliance is working to alter the current reality where
data are kept and studied in silos, and tools and
methods are non-standardized and incompatible”
(http://genomicsandhealth.org/). The hope is that a
more standardised approach to “tools and methods”
used for collection, storage and characterisation of data
will engender further improvements in the ease of data
sharing.
GS: Where open access imperatives and local
infrastructure meet
Whilst the emphasis coming from the wider science and
data sharing policy environment encourages the priori-
tisation of data sharing [48], translating this into practice
remains a local enterprise. Requirements for managing
access to resources held in biobanks and biorepositories
are inevitably interpreted at the level of projects, reposi-
tories or institutions [35]. The entwined discourse of
standardisation and open access would suggest that such
heterogeneity is detrimental. However, scholarship in the
field of science and technology studies suggests that des-
pite efforts at standardization, practice will necessarily
maintain some aspects of a given context [49]. Unlike
for example UK Biobank, GS has made a commitment
to oversee and manage overlap in the research goals of
applicants. Where it is likely that two separate applica-
tions would overlap, a situation that has arisen no more
than 10 times in the history of GS, leading to a potential
duplication of effort, GS offers to put the researchers in
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touch with the “Expert Working Group” (EWG) leads
(Fig. 1) [http://www.ed.ac.uk/generation-scotland/about/
management/expert-working-groups]. However, there is
no requirement for the applicant to collaborate with an
EWG. Academics closely associated with the resource as
part of the Expert Working Groups and the GS Execu-
tive Committee (Fig. 1) continue to invest their time and
intellectual capital in GS. Some of these academics were
involved in the scientific design of the study, the recruit-
ment of participants and convincing funders of its merit.
Moreover, they continue to be involved in what has been
termed ‘articulation work’ [50]. That is to say they (and
others) have sought research funding for a variety of
studies via which they have added further data to the re-
source, helping to maintain its relevance and scientific
importance.
The EWGs include high profile academics whose ex-
pertise covers a particular area of research. Whilst a de-
cision on the part of an applicant not to collaborate with
the EWGs does not necessarily create a barrier to access,
the EWGs constitute part of a commitment by GSAC to
manage project overlap. A distinctive feature of access
arrangements for GS relates to co-authorship, which is
stated in the data and materials transfer agreement and
the GS Authorship & Acknowledgement Policy [21]. GS
requires that collaboration with a research group
requesting access leads to shared authorship of research
publications resulting from use of the GS resource.
Whilst there are few sanctions that GS can apply to en-
sure compliance with this requirement for attribution of
credit, there is just one example of these terms not being
honoured from over 150 completed research projects
with more than 100 published research papers. Some ex-
perts in governance suggest that the independence of ac-
cess decisions form these sorts of contextual factors is
desirable [51]. However, this is arguably a way in which
the researchers and the repository can ensure reward
and continued ethical and scientific input are in place.
Principle 7 of the RCUK Concordat recognises the costs
to research teams involved in data sharing, emphasising
the importance of finding appropriate ways of acknow-
ledging and rewarding those who collect and manage
the data [37].
Requests for access to data only or data plus samples
are submitted via a secure online portal, where re-
searchers will also indicate whether linkage to NHS re-
cords or participant re-contact will be necessary. Four
areas of evaluation (scientific, governance, data and ma-
terials) are then completed by designated GSAC mem-
bers. The scientific assessment addresses questions
around the methods and scientific contribution of the
proposal. The governance assessment will often attempt
to balance ethical considerations such as confidentiality
guarantees and existing participant consents with details
of the requested access to the resource and participants.
Issues such as whether the participants will need to be
re-contacted and on what basis are dealt with here. On
one occasion, a proposal was declined as it asked for
specific phenotypic information which was thought
likely to raise sensitivities such as participants feeling
that they had been “singled out”. The data assessment is
usually done by a member of the GS management group
who also sits on the GSAC. This will consider the data
holdings of GS in respect of the type of data requested,
flagging up practical issues relating to release of data in-
cluding the relevant participant consent for linkage of
their GS data and medical records via the CHI number
for re-contact, or sharing samples outside the UK. For
example, if an applicant has requested the samples to be
sent overseas or has asked to re-contact participants, the
data assessment will include a report on the number of
individuals who have consented to this. On another oc-
casion a proposal requested unusually specific data relat-
ing to only a small number of individuals and was
returned with a request for an overhaul of the research
design, on the grounds that it could pose a potential re-
identification risk. The materials assessment is carried
out when samples as well as data are requested. This as-
sessment must consider whether the proposed research
is an appropriate use of the physical samples, which are
a finite resource. Projects looking simultaneously at mul-
tiple biomarkers in a high proportion of the cohort are
preferred to those which measure only one biomarker in
a small subset, as this creates more new data for the
quantity of sample used. The proposal form also in-
cludes sections on why the GS resource was chosen to
carry out the research and what benefits could be ex-
pected to accrue to GS as a result of providing access.
Applicants are asked about whether ethical approval has
been sought from their own institution, funder or other
appropriate body. How to ensure appropriate recogni-
tion of work done in creating and maintaining the bio-
bank in regard to each proposal is also a question that is
raised depending on the type and extent of access sought
[8]. Discussions during the GSAC meetings are in most
cases attempts to accommodate these various aspects of
the proposal alongside the question of sustainability of
the resource. Issues can be and often are resolved by
asking applicants for further information or modification
of the type and scope of access sought in line with the
concerns raised in the assessments, which are then dis-
cussed in the GSAC meetings.
Access and sustainability
GS access arrangements and the discussion conducted
as part of the GSAC meetings aim to strike a balance
that promotes the sustainability of the resource whilst
making it a ‘community resource’ [24]. One of the
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recommendations made by the EAGDA [36] is that re-
positories should be well-resourced, presumably to sup-
port the sort of activities that comprise the managed
access approach undertaken by GS. Following the end of
the period of funding from the Scottish Government,
the GS project manager and administrator posts have
been underwritten by a mixture of cost recovery charges
for access and financial support from an NHS Research
& Development fund. Cost recovery through access fees
payable by researchers wishing to access the GS resource
is a key part of sustainability, helping to maintain the
lean institutional structure necessary to the governance
and curation of the GS resource. It also provides an in-
centive to facilitate access, mitigating against any pos-
sible tendency towards withholding data [51]. Different
tiers of pricing are in place for access to data and sam-
ples by academic and commercial applicants. As cost re-
covery via access fees is an important component in the
sustainability of the study, it has been necessary to strike
a balance between meeting the real overhead costs of
maintaining GS and keeping charges at non-prohibitive
levels. A steadier source of income would undoubtedly
lead to a recalibration of current arrangements, which
lend another layer to the decision making process
around allowing access. At the time of writing, only four
projects have not gone ahead due to an unwillingness by
prospective secondary users to pay an access charge.
Sustainability questions also arise in relation to the
wider data sharing environment and the existence of
cost free alternatives to accessing genotype and pheno-
type data [19] broadly similar to that in GS. For ex-
ample, access can be sought to resources via routine
academic collaboration with the Principal Investigator of
different cohorts, or from genomics data resources such
as the EGA [34]. Another evolving aspect of the data en-
vironment impacting upon the GS biobank is requests
for data to be released so that it can be housed on plat-
forms elsewhere. This would diminish the position of
GSAC as a single gatekeeper of the data. A current ex-
ample can be seen in the collation and sharing of cohort
data via the MRC Dementias Platform UK (http://
www.dementiasplatform.uk/).Moves to release data into
scientific databases that are publically accessible or have
less or perhaps more restrictive modes of permitting ac-
cess raise uncertainties around ethics and governance po-
tentially creating ‘tremendous consent challenges’ [52].
The move in human genomics research towards collab-
orative working in very large international consortia, as
exemplified by the Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE) Consortium
(http://www.chargeconsortium.com/) also raise challenges
in terms of recognition of effort. GS is one of the cohorts
contributing data to CHARGE (and many other national
and international genomics consortia). These consortia
facilitate genome-wide association study meta-analyses
and replication opportunities among multiple large and
well-phenotyped longitudinal cohort studies. Data from
GS contributes towards greater statistical power for new
discoveries to be made and leads to co-authorship of
members of the GS Executive on the resulting research
papers. However, because data and summary statistics
from a large number of cohorts are combined in a meta-
analysis, there is a considerable distance between the
details and nuances of the governance of each individual
cohort and the data analytical research activities, such as
producing summary statistics, within the consortium. For
example, data analysts working in a consortium will usu-
ally not have been involved in the data access application
made to each repository. This disconnect is evidenced by
the resulting research papers often being co-authored by
hundreds of researchers, with the description of each co-
hort usually confined to the online supplementary infor-
mation. It also again raises potential ethical questions
around expectations embedded in relationships between
study participants and data producers [30, 33].
Attempts to mitigate these sorts of concerns can be
seen in to the central genomics database dbGaP, where
emphasis has been place upon the independence of the
Data Access Committees (DACs) of this resource [51].
Independence in this scenario is interpreted as ‘without
the involvement of data producers’ [51]. Other examples
of this sort of centralised structure for managing access
can also be found in the UK. For example, the Wellcome
Trust Sanger Institute DAC manages access to data as-
sembled for the Wellcome Trust Case Control Consor-
tium and other projects located there [53]. While there
is an increasingly acknowledged need to attribute credit
for the role played by repositories such as GS, these ef-
forts remain partial and aspirational in terms of setting
standards [51]. Moreover, these efforts again appear to
lean toward harmonisation to facilitate a decontextual-
isation of the data. However, context can be important
both in terms of the significant time invested by re-
searchers in the creation and maintenance of the reposi-
tory and in regard to relationships with the study
participants [8, 16]. Questions of how to incorporate the
specifics of local practices, which respond to both
sustainability issues and the expectations of research
subjects within these large multi-repository, multi-
institutional arrangements, are not directly addressed by
ensuring the independence of Data Access Committees
for repositories with a centralised governance system.
Managing access to an evolving resource
One of the problems of attempting to produce enduring
standardised access procedures is that unlike Access
Committees, written protocols cannot respond to rele-
vant developments both within and outside of individual
Heeney and Kerr BMC Medical Ethics  (2017) 18:80 Page 7 of 11
biobanks. The emphasis place upon informed consent
can be seen as problematic in this regard [16]. In the
decade since GS began recruitment there have been
changes both in the wider data sharing environment and
in the composition of the repository itself. Written con-
sent was sought and gathered during the original GS re-
cruitment phase (from 2006) for study data to be linked
to the NHS health records of participants, using their
CHI number. This identifying number is used for all
NHS Scotland procedures (registrations, attendances,
samples, prescribing and investigations) and allows
healthcare records for individuals to be linked across
time and location [20]. Ethical approval for the record
linkage was obtained (as part of the GS:SFHS Research
Tissue Bank Approval) from the East of Scotland
Research Ethics Committee. In each record linkage pro-
ject, permissions were obtained by researchers from the
NHS Privacy Advisory Committee or its successor, the
Public Benefit and Privacy Panel for Health and Social
Care, for use of NHS medical data. The number of
events, and measurements recorded, increase over time
as the participants get older, which means there is an
enormous additional pool of research relevant data
about GS participants obtained since recruitment.
Although initial data collection was cross-sectional, GS
became a prospective cohort as a result of the ability to
link to routine NHS data [54]. This makes the GS
resource valuable for a new generation of researchers
with evolving methodical and technological tools. In
large part due to the existence of the Scottish CHI
number and participant consent, GS is able to link to
NHS records, wherein the scale of the data is vast. For
example, in the biochemistry dataset alone, there are
more than two million test results for over 800 measures
relating to 11,000 GS participants in NHS Tayside, going
back over 25 years. In a recent genomics research pro-
ject using the GS resource, outputs from just over two
thousand participants for one of these biochemical mea-
sures, uric acid, were tested for association with over 24
million genetic markers in a genome-wide association
study (GWAS) [55]. Such research, employing new tech-
niques including genotype data imputation, continues to
augment the number of data items held on individual
study participants within the repository.1
GS and evolving participant consent
Alongside anonymisation of data, informed consent is a
standard tool for ensuring data access remains ethical in
the face of such dynamic developments. It was acknowl-
edged from the outset that it would be difficult to pre-
dict the precise nature of use of the GS resource in the
future. For that reason, and due to the logistics and po-
tential confidentiality challenges of contacting and re-
consenting individual participants for each use, broad
consent was sought. This was intended to permit a very
wide range of potential biomedical research (including
commercial) uses.2 These documents have been subject
to minor updates to reflect changes in the project. The
latest versions (from early 2010) contain information re-
lating to access to the resource and the management
and protection of participant data. It is made clear that
“Any access will be subject to the strictest ethical scru-
tiny and scientific rigour’ (GS PIL 2010). Generation
Scotland participants originally consented to their data
being made available to researchers from any sector
worldwide. However, this original consent did not specif-
ically allow samples to leave the UK, so additional con-
sent for samples to be sent abroad was later obtained for
a little under half the cohort (Table 1).
This additional consent was achieved via a re-contact
exercise carried out in 2012–3 in response to several re-
quests to allow the materials and data to be analysed using
technologies only available in other countries. Re-contact
for consent, as with all re-contact with study participants,
was done through an established mechanism that, again,
used the CHI number, with letters sent by post by an NHS
intermediary for confidentiality. GS saw this as the most
appropriate means to ensure scientifically and ethically
valid research was not declined on the basis of the loca-
tion of the laboratories. The additional consent process re-
quired a submission to a Research Ethics Committee and
took well over a year from initiation to conclusion. It came
at a considerable cost in terms of GS staff time and the
non-negligible cost of postage to and from 21,207 individ-
uals (88% of the 24,084 people in the study database, ex-
cluding participants who had died or who had not given
consent for re-contact). Just over half this number replied
with 11,255 participants giving consent for their samples
to leave the UK (53% of people contacted in total). The
decision to reconsent was a response to unforeseen
changes in the scientific environment and clearly illus-
trates the reality of the challenges to relying upon consent
Table 1 Summary of consents in the GS resource at baseline
(2006–2011) and added subsequent to the end of participant
recruitment in 2011
Dataset Date in GS Participant numbers
Participants recruited 2006–2011 24,084
Participants with consent and
mechanism for record linkage
2006–2011 22,014
Participants with consent and
mechanism for recontact
2006–2011 21,992a
Participants with consent for
sample transfer ex-UK
2012–2013 11,255
Participants with consent for
recontact by email
2016 6546
aThis figure includes 785 participants known to have died since participation
in GS
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as a unique means of ensuring that changing access prac-
tices are rendered ethical [32]. Although policy makers
dealing with the protection of health data are taking an in-
creasingly permissive view about the relationship between
consent and access to medical records [39], GS continues
to employ a consent based approach for use of these data.
The joint report from the UK National Data Guardian
was clear on the responsibility of organisations using
NHS data to ensure not only appropriate consent but
also anonymity of disseminated data [38]. Due to the de-
tailed and potentially identifiable nature of the data col-
lected in GS, it was agreed from the outset that the data
would be released using a managed access policy [21].
From a technical point of view the duty to protect par-
ticipant data from identification is dealt with by GS via
IT and access arrangements. GS study participants’ in-
formation is protected by personal identifiers being held
separately from all other study data, using an encrypted
version of the CHI number. The encryption key is held
within the NHS IT network and cannot be directly
accessed by GS. Researchers as part of their host institu-
tion have to sign a Data User Agreement before they are
allowed to access NHS-linked data. Linked eHealth data is
released for clinical academic research via NHS approved
safe havens, or held in a secure network environment
[56]. Samples are stored in fo ur separate laboratories in
Scottish University Medical Schools, catalogued through a
central laboratory information management system [57].
Only the GS management team holds the key between the
sample identifiers and the phenotype data. These mea-
sures are designed to ensure that GS samples, which in-
clude DNA, blood, serum and urine, are not accessed
without the appropriate authorisation via the access pro-
cesses detailed above. Knowledge of these systems for pro-
tecting the data, the data subjects and reputation of the
repository is part of what members of the GSAC bring to
decisions about data release.
Discussion
One of the issues highlighted in the paper is the inter-
action between specific local characteristics of a given bio-
bank or repository, especially in relation to governance
and sustainability, and the guidelines and ideals pervading
the wider data sharing and science policy and ethics envir-
onment, which aim at harmonisation and fewer barriers
to access [19]. The aim is to show how this policy context
translates into the ways in which data is accessed and eth-
ics and governance are enacted, given factors local to the
repository and its practices. One part of this is the ability
to respond to what is non-routine, as well as what was not
foreseen when consent arrangements were entered into
originally [17]. The GSAC in its decision-making must
consider and accommodate a number of issues, in which
it is difficult to make a clean separation between questions
of sustainability, governance and ethics. GSAC routinely
discusses issues relating to the welfare of the data subjects,
how further recontacts may be unduly onerous and
whether or not a particular request for new data may
make the data subject question their health status. Such
questions relate to the continued goodwill of participants
and raise sustainability considerations as do sharing ar-
rangements which do not adequately recognise the aca-
demic and administrative work involved in providing GS
data. Commitment of academics involved with the re-
source through the EWGs, the Executive Committee and
the GSAC is an important part of ensuring that the gov-
ernance model agreed to by participants is maintained.
In considering requests for access, GSAC must “ensure
the Project, through its collaborations, conforms to the
consent and ethical approval obtained, is not brought
into disrepute and that participant confidentiality is
respected” (Generation Scotland Management, Access
and Publications Policy 2016). The work on ethics done
by GSAC and the Management Group is interrogating
what is being proposed to ensure continued alignment
between the governance framework, participant expecta-
tions, the ability to manage the resource and strong en-
couragement from the scientific community to be as
open as possible [36]. The first research proposal was
approved by GSAC in 2008 (at a time when participant
recruitment and data collection were ongoing) and the
first research findings resulting from an access request
were published in 2010. Nearly a decade after its forma-
tion, GSAC remains actively involved in mediating im-
peratives to promote access and ethical and sustainable
research and management of the GS resource. We sug-
gest that in addition to the focus upon ever more univer-
sal and standardised practices, the local expertise gained
in the management of such repositories must also be
nurtured and encouraged [49].
Conclusions
In summary, a commitment to open access in genomics
research has found substantial backing in science and
health policy circles in the UK and beyond, as evidenced
by the stance taken by research funders and the outputs
of influential meetings such as those held in Bermuda,
Fort Lauderdale and Toronto. This is not to stay that
stakeholders are unaware of or unsympathetic to the is-
sues around data subject privacy and to a lesser extent
the interests of the data-producing scientists and institu-
tions (both of which are mentioned in the Toronto
Statement). However, in this paper we have attempted to
throw light on how decisions on access sustainability
can figure in solutions to potential problems for both
data-producing scientists and research participants.
Repositories of data and samples from human subjects
may have to operate under managed access, to protect
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privacy, align with the participant consent and ensure
that the resource can be managed in a responsive and
sustainable way. Research on best-practice which looked
at literature produced by stakeholders also found that
some of the questions we have raised here, such as con-
tinuing to balance the interests of different stakeholders,
fulfilling commitments to research participants and the
ability to control analyses that may cause reputational
damage, were ranked among the disadvantages of data
sharing [30]. We have used our own engagement with
GS in order to construct an argument about the import-
ance of considering the local aspects to responsively ac-
commodate access policies designed for universal
application. Data access committees need to be reflexive
and flexible, to cope with changing technology and op-
portunities and threats from the wider data sharing en-
vironment. These considerations are particularly relevant
in relation to closure of a biobank [19, 58] an event that
raises practical issues such as transfer of data or materials
to other entities [59]. We have aimed to show that the re-
sponsive ethics work done by GSAC and counterparts in
other smaller repositories is key in mediating between the
global and the local [59] in the era of consortium working.
Whilst ever greater emphasis is placed upon open access
to data as a commercial and economic good, some mech-
anism for incorporating the role now carried out by the
access committee will remain necessary.
Endnotes
1
Baseline Phenotype
(GS clinic visit)
2006–2011 3,228,900 (21,526 × 150)
Baseline Phenotype
(GS Pre-Clinic Questionnaire)
2006–2011 9,439,200 (23,598 × 400)
Genotype (genome-wide,
after QC and imputation)
2013–2016 24,111,857 imputed genetic
variants (20,032 IDs)
NHS EHR phenotype
(biochemistry tests)
2014–2015 2,192,346 (11,125 IDs)
NHS EHR phenotype
(hospital in-patient episodes)
2012–2015 106,492 (18,687 IDs)
2Examples of consent forms and Participant
Information Leaflets can be viewed on the GS website
(www.generationscotland.org).
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